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OBJECTIVE — To evaluate the impact of former intensive versus conventional insulin treat-
ment on neuropathy in Diabetes Control and Complications Trial (DCCT) intensive and con-
ventional treatment subjects with type 1 diabetes 13–14 years after DCCT closeout, during
which time the two groups had achieved similar A1C levels.
RESEARCH DESIGN AND METHODS — Clinical and nerve conduction studies
(NCSs) performed during the DCCT were repeated during the Epidemiology of Diabetes Inter-
ventions and Complications (EDIC) study by examiners masked to treatment status on 603
former intensive and 583 former conventional treatment subjects. Clinical neuropathy was
deﬁnedbysymptoms,sensorysigns,orreﬂexchangesconsistentwithdistalpolyneuropathyand
conﬁrmed with NCS abnormalities involving two or more nerves among the median, peroneal,
and sural nerves.
RESULTS — The prevalence of neuropathy increased 13–14 years after DCCT closeout from
9 to 25% in former intensive and from 17 to 35% in former conventional treatment groups, but
the difference between groups remained signiﬁcant (P  0.001), and the incidence of neurop-
athy remained lower among former intensive (22%) than former conventional (28%) treatment
subjects (P  0.0125). Analytic models of incident neuropathy that adjusted for differences in
NCS results at DCCT closeout showed no signiﬁcant risk reduction associated with former
intensive treatment during follow-up (odds ratio 1.17 [95% CI 0.84–1.63]). However, a signif-
icant persistent treatment group effect was observed for several NCS measures. Longitudinal
analyses of overall glycemic control showed a signiﬁcant association between mean A1C and
measures of incident and prevalent neuropathy.
CONCLUSIONS — The beneﬁts of former intensive insulin treatment persisted for 13–14
years after DCCT closeout and provide evidence of a durable effect of prior intensive treatment
on neuropathy.
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T
he Diabetes Control and Complica-
tions Trial (DCCT) enrolled 1,441
patients with type 1 diabetes and
randomly assigned them to intensive or
conventional treatment. The DCCT con-
clusivelydemonstratedthatreducingglu-
cose levels delayed or prevented the
development of retinopathy, nephropa-
thy, and neuropathy over a mean of 6.5
years (1). At DCCT closeout, subjects
were encouraged to maintain or begin in-
tensivetreatmentandwereinvitedtopar-
ticipate in a prospective observational
study (Epidemiology of Diabetes Inter-
ventions and Complications [EDIC]) to
evaluate the long-term effects of prior
treatmentonmicrovascular,neuropathic,
and macrovascular outcomes (2).
AtDCCTcloseout,themeanA1Cwas
signiﬁcantly lower in the intensive com-
pared with the conventional treatment
group (7.4 vs. 9.1%, P  0.0001). How-
ever,within1year,thedifferencesinA1C
narrowed substantially (7.9% intensive
vs. 8.3% conventional, P  0.0001), and
within 5 years the A1C levels no longer
differed between groups (8.1% intensive
vs.8.2%conventional,P0.11).Despite
similar A1C levels, former intensive treat-
ment subjects continued to have a lower
cumulative incidence of retinopathy and
nephropathy than conventional treat-
mentsubjects(3–5).Thispersistenteffect
of past glucose control has been termed
metabolic memory (6). Previously pub-
lished EDIC study results showed a dura-
ble effect of former intensive treatment
compared with former conventional
treatment on symptoms and signs of neu-
ropathy,basedonaneuropathyscreening
tool, 8 years after DCCT closeout (7). The
neuropathy screening tool initially used
during EDIC differed, however, from the
more comprehensive methods used dur-
ing the DCCT (2,8).
The current study (NeuroEDIC) was
performed to determine the impact of
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metrical neuropathy during the EDIC
study using the same comprehensive
measures of neuropathy performed dur-
ing the DCCT. We report neuropathy
outcomes in the EDIC cohort based on
original intention-to-treat DCCT treat-
ment group assignments, with glycemic
exposurereﬂectingthedifferencesinA1C
during 6.5 years of the DCCT and the
subsequent convergence of A1C for al-
most14yearsafterDCCTcloseoutduring
the EDIC study. The comprehensive as-
sessment of peripheral neuropathy al-
lowed us to examine whether the
signiﬁcant treatment group differences in
symptoms, signs, and electrophysiologi-
cal features of neuropathy at DCCT close-
outhavepersisted13–14yearslaterandif
metabolicmemoryappliestoneuropathy.
RESEARCH DESIGN AND
METHODS— The DCCT design has
been described elsewhere (1). Brieﬂy, we
recruited 1,441 subjects with 1–15 years
durationoftype1diabetes,minimalorno
microvascular complications, and no his-
tory of neuropathy requiring medical
treatment. Subjects were randomly as-
signed to intensive treatment (three or
more insulin injections daily or continu-
ous subcutaneous insulin infusion,
guided by frequent self-monitoring of
blood glucose) or conventional treatment
(one or two insulin injections daily) and
followed for 4–9 years (mean 6.5 years)
(1,9). The DCCT included a primary pre-
vention cohort and a secondary interven-
tion cohort. The primary prevention
cohort had diabetes for 1–5 years (mean
2.6 years) and no retinopathy or mi-
croalbuminuria at baseline. The second-
ary intervention cohort had diabetes for
1–15 years (mean 8.7 years) and mild to
moderate retinopathy at baseline. The
secondary intervention cohort also had a
higher prevalence of conﬁrmed clinical
neuropathy at DCCT baseline than the
primary prevention cohort (9.4 vs. 3.5%,
respectively) (8).
Of 1,305 subjects from the original
DCCT cohort who were active in the
EDIC study, 1,186 agreed to participate
inNeuroEDIC.Theseincluded603inthe
formerintensivetreatmentgroupand583
in the former conventional treatment
group, representing 93 and 91% of eligi-
ble participants, respectively.
Clinical neurological examination
Neurologists masked to treatment group
assignment performed the clinical exam-
inations as in the DCCT, including neu-
rological history and physical
examination to detect the presence of dis-
tal symmetrical polyneuropathy, and
identiﬁed potential causes of neuropathy
other than diabetes (1).
Nerve conduction studies
Nerve conduction studies (NCSs) were
performed by trained and certiﬁed elec-
tromyographers on the dominant side
median (motor and sensory), peroneal
(motor), and sural (sensory) nerves using
percutaneous nerve stimulation and sur-
face recording as done in the DCCT (10).
NCS responses were evaluated by an in-
dependent reviewer to identify outlying
or nonphysiological values and measure-
ment, transcription, and calculation er-
rors. Records thought to be in error were
returned to the electromyographers for
remeasurement and resubmission. Nor-
mal values were based on those provided
by participating laboratories during the
DCCT(10).AnabnormalNCSresultcon-
sistent with neuropathy was deﬁned as a
value above or below the absolute thresh-
old of normal among amplitude, conduc-
tion velocity, or F wave latency in at least
two anatomically distinct nerves (1,10).
Neuropathy outcome measures
Neuropathy was deﬁned using clinical
and electrodiagnostic criteria (1). As in
the DCCT, the classiﬁcation of deﬁnite
clinicalneuropathywasbasedontheneu-
rologist’s examination and required at
leasttwopositiveresponsesamongsymp-
toms, sensory signs, or reﬂex changes
consistent with a distal symmetrical poly-
neuropathy (e.g., symptoms or signs
showingalength-dependentgradientina
stocking or stocking-glove distribution).
Conﬁrmed clinical neuropathy, the pri-
mary outcome measure, also required
NCSabnormalitiesinvolvingtwoormore
nerves among the median, peroneal, and
sural nerves. The components of the clin-
ical and NCS examinations were second-
ary outcome measures. The DCCT
deﬁnition of conﬁrmed clinical neuropa-
thy permitted conﬁrmation based on ab-
normal autonomic nervous system test
results. However, only 12 subjects ful-
ﬁlled that criterion, and conﬁrmation of
neuropathy in these analyses was based
on NCS abnormalities appropriate for a
sensory or sensorimotor polyneuropathy
without regard to autonomic test results.
The online appendix (available at
http://care.diabetesjournals.org/cgi/content/
full/dc09–1941/DC1) includes descrip-
tions of the surface temperature measures
obtained during the NCSs, the statistical
methods, and the results of analyses
within the primary prevention and sec-
ondary intervention cohorts. Analyses re-
portedhereareforthecombinedcohorts.
RESULTS
Participants
The characteristics of the 1,186 Neu-
roEDIC participants at DCCT baseline,
DCCT closeout, and EDIC years 13–14
are shown in Table 1. Characteristics of
theprimarypreventionandsecondaryin-
tervention cohorts are shown in supple-
mental Table 1a. There were no clinically
relevant treatment group differences in
the characteristics, or in the use of medi-
cations to reduce neuropathic pain, or in
theuseofACEinhibitorsorangiotensinII
receptor blockers (ARBs). The Neu-
roEDIC participants were comparable
with 121 active and surviving DCCT par-
ticipants who did not participate in the
NeuroEDIC, except that the NeuroEDIC
participants at EDIC years 13–14 were
slightly older than nonparticipants (aged
48 vs. 46 years, P  0.01).
Neuropathy status during DCCT and
NeuroEDIC
The prevalence of clinical and NCS indi-
cators of neuropathy at DCCT baseline,
DCCT closeout, and EDIC years 13–14
are shown in Table 2 by DCCT treatment
group in the total cohort. At DCCT base-
line, there were no signiﬁcant between-
treatment group differences for any of the
results, and the overall prevalence of con-
ﬁrmed clinical neuropathy was low (7%
intensive vs. 5% conventional treatment,
P  NS). At DCCT closeout, the treat-
ment groups differed in most measures of
neuropathy, with lower prevalence of
neuropathy in the intensive compared
with the conventional treatment group (9
vs. 17%, P  0.001).
At EDIC years 13–14, the prevalence
of all indicators of neuropathy had in-
creased relative to DCCT closeout. Al-
though the difference between treatment
groups had narrowed, the prevalence of
clinicalsymptomsandsigns(abnormalsen-
sation) and of the clinical neuropathy out-
come measure remained lower in the
former intensive treatment group com-
pared with the former conventional treat-
ment group. The prevalence of abnormal
NCS results also increased in both treat-
mentgroupsrelativetoDCCTcloseout,and
the between-treatment group difference
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tensive vs. 68% former conventional treat-
ment,P0.001).Similarly,theprevalence
of conﬁrmed clinical neuropathy increased
substantially in both treatment groups, and
thebetween-groupdifferenceremainedsig-
niﬁcant (25% former intensive vs. 35%
formerconventionaltreatment,P0.001).
The results are shown separately
within the primary prevention and sec-
ondary intervention cohorts in supple-
mental Table 2a. At each evaluation, the
prevalences of most indicators of neurop-
athy were higher in the secondary inter-
vention cohort than in the primary
prevention cohort. At EDIC years 13–14,
the primary prevention cohort showed a
signiﬁcant treatment group difference
only in the prevalence of abnormal NCS
results, whereas the secondary interven-
tion cohort showed signiﬁcant treatment
group differences in the prevalence of all
measures of neuropathy except abnormal
reﬂexes.Similarly,thebetween-treatment
group difference in prevalence of con-
ﬁrmedclinicalneuropathywassigniﬁcant
in the secondary prevention cohort (29%
former intensive vs. 42% former conven-
tional treatment, P  0.01) but not in the
primary prevention cohort (22% former
intensive vs. 28% former conventional
treatment, P  NS).
NCS results
NCS results at DCCT baseline, DCCT
closeout, and EDIC years 13–14 are sum-
marized in Table 3, with the median
(50th),5th,and95thpercentilevaluesfor
each attribute by treatment group. At
DCCT baseline, there were no signiﬁcant
between-group differences for any of the
individual NCS attributes or for the over-
all test of stochastic ordering. At DCCT
closeout, there were treatment group dif-
ferences in most NCS results. Perfor-
mance was generally worse (e.g., lower
amplitude,slowerconductionvelocity,or
longer F wave latency) for the conven-
tionaltreatmentgroupcomparedwiththe
intensive treatment group. At DCCT
closeout, the Wei-Lachin test (11) of the
overall difference between groups in all
10NCSmeasuressimultaneouslyshowed
a signiﬁcant favorable effect of intensive
therapy.
During EDIC years 13–14, all NCS
results showed substantial deterioration
from DCCT closeout. The median (50th
percentile) NCS values were character-
ized by low sensory amplitudes, low sen-
sory and motor conduction velocities,
and prolonged F wave latencies. Many
values approached or exceeded the upper
orlowerlimitofnormal.Despitesubstan-
tial deterioration, NCS performance was
stillbetterintheformerintensivethanthe
former conventional treatment group.
However, the differences between treat-
ment groups were smaller at EDIC years
13–14 than at DCCT closeout, and the
level of signiﬁcance (based on the overall
Table 1—Characteristics of NeuroEDIC participants at DCCT baseline, DCCT closeout, and
EDIC years 13–14
Characteristic DCCT baseline DCCT closeout
EDIC
years 13–14
Age (years)
INT (n  603) 27  7* 34  7* 48  7*
CONV (n  583) 27  73 3  74 7  7
Female
INT 294 (49) 294 (49) 294 (49)
CONV 268 (46) 268 (46) 268 (46)
Height (cm)
INT 171  10 172  10 171  9
CONV 172  10 172  10 173  10
Weight (kg)
INT 68  11 78  14† 84  17
CONV 70  13 75  13 84  17
BMI (kg/m
2)
INT 23  32 7  4† 29  5
CONV 24  32 5  32 8  5
BMI 30 (kg/m
2)
INT 7  1 115  20† 202  34
CONV 10  22 7  5 173  30
Diabetes duration (years)
INT 6  41 2  52 6  5
CONV 6  41 2  52 6  5
A1C (%)
INT 9.1  1.6 7.3  1.0† 7.8  1.2
CONV 8.9  1.6 9.1  1.5 7.8  1.2
Systolic blood pressure (mmHg)
INT 113  12† 116  11 121  14
CONV 115  12 116  12 120  14
Diastolic blood pressure (mmHg)
INT 72  97 5  97 4  9
CONV 73  97 4  97 3  9
Total cholesterol (mg/dl)
INT 177  33 180  31 176  36
CONV 174  33 183  36 173  35
LDL cholesterol (mg/dl)
INT 111  29 112  27 103  30
CONV 108  29 114  31 100  31
Current smoker
INT 125 (21) 134 (22) 87 (14)
CONV 111 (19) 119 (20) 79 (14)
Any ACE inhibitors or angiotensin
receptor II blockers‡
INT 290 (48)
CONV 301 (52)
Medication for neuropathic pain
in hands/feet
INT 41 (7)
CONV 35 (6)
Data are means  SD or n (%). *P  0.05 former intensive treatment group (INT) vs. former conventional
treatment group (CONV). †P  0.01 INT vs. CONV. ‡Data on medication use was not collected during the
DCCT.
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less (Table 3).
The secondary intervention cohort
generally showed poorer NCS perfor-
mance (greater deviation from normal)
than the primary prevention cohort (sup-
plementalTable3a).Thetreatmentgroup
differences in NCS results at DCCT close-
out were consistent across the primary
prevention and secondary intervention
cohorts. Between-treatment group differ-
ences persisted at EDIC years 13–14 but
were smaller, particularly among the pri-
mary prevention cohort.
Measures of incident neuropathy
Table 4 shows the incidence of clinical
and NCS indicators of neuropathy at
DCCT closeout and EDIC years 13–14
among subjects who did not fulﬁll the
speciﬁc criterion for neuropathy at the
preceding evaluation. At DCCT closeout,
theincidencesofall measuresofneurop-
athy and of conﬁrmed clinical neurop-
athy (6 vs. 14%, P  0.001) were
signiﬁcantly lower in the intensive
treatment group compared with the
conventional treatment group. At EDIC
years 13–14, the incidences of all mea-
sures of neuropathy had increased sub-
stantially in both treatment groups
relative to DCCT closeout, and the only
signiﬁcant difference between groups
was in the incidence of conﬁrmed clin-
ical neuropathy (22% former intensive
treatment vs. 28% former conventional
treatment, P  0.0125).
The results of the analyses of incident
neuropathy for the primary prevention
and secondary intervention cohorts are
shown in supplemental Table 4a. The in-
cidence of all measures of neuropathy at
DCCT closeout and EDIC years 13–14
was higher in the secondary intervention
cohort than the primary prevention co-
hort. At EDIC years 13–14, no signiﬁcant
treatment group differences existed for
anymeasureofincidentneuropathyinei-
ther cohort.
Supplemental Table 5a presents the
odds of developing clinical neuropathy,
abnormal NCS results, or conﬁrmed clin-
ical neuropathy at DCCT closeout and at
EDIC years 13–14 among subjects who
did not fulﬁll the speciﬁc criterion for
neuropathy at DCCT closeout. As previ-
ously reported (8,10), a signiﬁcant treat-
ment group effect was found for all
measures of incident neuropathy at
DCCT closeout favoring intensive treat-
ment compared with conventional treat-
ment (P  0.001). At EDIC years 13–14,
the original treatment group assignment
continued to affect the incidence of con-
ﬁrmed clinical neuropathy, reducing the
odds of developing conﬁrmed clinical
neuropathy 13–14 years after DCCT
closeout (odds ratio [OR] 0.70 [95% CI
0.52–0.93]). However, as previously
shown(12),amongsubjectswithoutclin-
icalneuropathyatDCCTcloseout,thein-
tensive treatment group still had
signiﬁcantly better NCS results versus the
conventional treatment group. In addi-
tional models that adjusted for the aver-
age rank of selected NCS results at DCCT
closeout, the former intensive treatment
group no longer showed a signiﬁcant ef-
fect on incident neuropathy during the
EDICstudy.Forexample,theORforcon-
ﬁrmed clinical neuropathy was 1.17
(0.84–1.63), indicating that the long-
term difference in incident neuropathy
observed during the EDIC study was ex-
plainedbythesesubclinicaldifferencesin
NCS results at DCCT closeout among
subjectswhodidnothaveconﬁrmedclin-
ical neuropathy. For each outcome, an
optimal subset model was constructed,
and the best model was selected based on
the lowest value of the Akaike Informa-
tion Criterion (13). The selected covari-
ates are shown in supplemental Table 5a,
although all models gave similar results.
Analyses also investigated the differ-
ences between the former treatment
groups in the ranks of the NCS measures
at EDIC years 13–14 among subjects
without conﬁrmed clinical neuropathy at
DCCTbaselineorcloseoutafteradjusting
for the average NCS rank at DCCT close-
out. The Wei-Lachin test of no difference
between groups for all 10 quantitative
NCSmeasuressimultaneouslyshowedan
aggregate signiﬁcant beneﬁt of former in-
tensive versus conventional treatment
(P0.0032).AdditionalANCOVAmod-
els of each quantitative NCS measure at
EDIC years 13–14 that likewise adjusted
for DCCT closeout NCS results showed
nominally signiﬁcantly better perfor-
mance for the former intensive treatment
group versus the former conventional
treatment group in three of the NCS mea-
sures,allinthelowerextremity,including
peroneal amplitude (P  0.0082), sural
amplitude (P  0.0070), and sural con-
duction velocity (P  0.0255). These re-
sults were similar for models with and
without limb temperature adjustments.
Inﬂuence of glycemic control during
the DCCT and the EDIC study on
neuropathy
The effect of glycemic control on indica-
torsofincidentandprevalentneuropathy
Table 2—Prevalence of clinical (symptoms and signs) and NCS results suggestive of distal
symmetrical polyneuropathy at DCCT baseline, DCCT closeout, and EDIC years 13–14
Variable DCCT baseline DCCT closeout EDIC years 13–14
Clinical examination
Symptoms
INT 32 (5) 44 (7)* 119 (20)†
CONV 39 (7) 75 (13) 172 (30)
Abnormal sensation
INT 128 (21) 147 (25)† 248 (41)*
CONV 120 (21) 206 (36) 292 (50)
Abnormal reﬂexes
INT 105 (18) 135 (23)† 264 (44)
CONV 93 (16) 212 (37) 292 (50)
Clinical neuropathy
INT 57 (10) 88 (15)† 204 (34)†
CONV 48 (8) 128 (22) 240 (41)
Electrophysiology
Abnormal NCS
INT 185 (31) 164 (28)† 326 (54)†
CONV 196 (34) 288 (50) 401 (69)
Primary outcome
Conﬁrmed clinical neuropathy
INT 39 (7) 52 (9)† 152 (25)†
CONV 31 (5) 97 (17) 204 (35)
Data are n (%). *P  0.01 former intensive treatment group (INT) vs. former conventional treatment group
(CONV). †P  0.001 INT vs. CONV.
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level during the DCCT and during the
EDIC study. Supplemental Table 6a pre-
sents the OR of developing or having the
particular indicator of neuropathy per
unitA1Cpercentincrease(e.g.,8vs.7%),
given that all other variables were held
constant. The mean A1C level during the
DCCT was signiﬁcantly associated with
the incidence of conﬁrmed clinical neu-
ropathy and with the prevalence of all
measures of neuropathy at EDIC years
13–14. Similarly, the mean A1C level
during the EDIC was a signiﬁcant predic-
tor of all measures of incident and preva-
lent neuropathy at EDIC years 13–14.
The odds of developing emergent con-
ﬁrmed clinical neuropathy during the
EDIC study increased signiﬁcantly per
unit(%)increaseinmeanA1Cduringthe
DCCT (OR 1.24 [95% CI 1.10–1.41])
and during the EDIC study (1.82 [1.55–
2.14]). The odds of having conﬁrmed
clinical neuropathy at EDIC years 13–14
(prevalence) likewise increased signiﬁ-
cantly per unit increase in mean A1C
during the DCCT (1.35 [1.35–1.50])
and during the EDIC study (1.80
[1.56–2.07]).
CONCLUSIONS— Intensive treat-
ment designed to achieve near-normal
glycemia among patients with type 1 dia-
betes delayed or prevented the develop-
mentofneuropathyoveranaverageof6.5
years in the DCCT (1). The differences in
retinopathy and nephropathy associated
with intensive versus conventional treat-
ment persisted after differences in A1C
levels dissipated, supporting the concept
of metabolic memory (6). Less rigorous
cross-sectional evaluations of neuropathy
performedatEDICyear8showedthatthe
beneﬁtsof6.5yearsofintensivetreatment
had persisted (7), a ﬁnding consistent
with other beneﬁcial effects of metabolic
controlonneuropathy(14–16).Informa-
tion about incident or progressive neu-
ropathy among EDIC participants was
limited, however, because the neuropa-
thymeasuresusedduringtheinitialEDIC
evaluations differed from those used in
the DCCT. The current NeuroEDIC eval-
uations address this concern by using the
Table 3—NCS results at DCCT baseline, DCCT closeout, and EDIC years 13–14
Nerve/attribute DCCT baseline DCCT closeout EDIC years 13–14
Median motor
Amplitude (abnormal limit 4.2) (mV)
INT 10.2 (4.5–17.5) 10.1 (5.0–16.0) 8.8 (4.2–14.8)
CONV 10.0 (4.5–17.0) 10.0 (5.0–16.0) 8.9 (4.0–14.4)
Conduction velocity (abnormal limit 49.0) (m/s)
INT 54.0 (46.5–61.2) 55.0 (48.0–61.1)† 51.4 (42.5–58.2)*
CONV 53.8 (46.9–60.3) 52.3 (44.2–59.3) 51.0 (42.9–57.7)
F wave latency (abnormal limit 31.8) (ms)
INT 28.0 (24.0–33.0) 27.6 (24.1–32.1)† 29.5 (25.4–35.0)
CONV 28.0 (24.0–32.6) 28.8 (24.8–34.0) 29.9 (25.6–36.4)
Median sensory
Amplitude (abnormal limit 10.0) (V)
INT 19.0 (7.0–47.0) 15.0 (5.0–45.0) 9.0 (0.0–29.0)
CONV 20.0 (7.0–50.0) 14.0 (3.0–40.0) 8.0 (0.0–29.0)
Conduction velocity (abnormal limit 48.0) (m/s)
INT 51.8 (38.2–63.4) 51.8 (36.8–62.0)† 43.8 (25.9–57.9)
CONV 52.1 (39.4–64.0) 50.0 (33.0–61.0) 43.1 (25.9–56.8)
Peroneal motor
Amplitude (abnormal limit 2.5) (mV)
INT 5.6 (2.0–10.0) 5.8 (2.0–10.0)† 4.2 (0.3–9.0)†
CONV 5.5 (2.0–10.9) 5.0 (1.1–10.0) 3.5 (0.1–7.6)
Conduction velocity (abnormal limit 40.0) (m/s)
INT 43.7 (35.5–51.5) 45.0 (37.0–52.0)† 42.1 (30.5–49.3)†
CONV 43.8 (35.6–50.9) 41.5 (33.0–49.0) 40.6 (25.7–47.8)
F wave latency (abnormal limit 56.0) (ms)
INT 50.4 (41.6–61.6) 50.6 (42.0–69.8)† 53.3 (43.9–74.0)†
CONV 50.8 (40.4–62.0) 54.5 (42.9–69.8) 55.5 (45.1–74.0)
Sural sensory
Amplitude (abnormal limit 5.0) (V)
INT 12.0 (0.0–28.0) 11.0 (0.0–27.0)† 7.0 (0.0–18.0)†
CONV 13.0 (0.0–30.0) 9.0 (0.0–23.0) 5.0 (0.0–15.0)
Conduction velocity (abnormal limit 40.0) (m/s)
INT 45.1 (35.0–56.0) 45.2 (35.9–56.0)† 42.4 (29.8–51.9)†
CONV 45.2 (34.1–56.0) 42.4 (34.6–52.0) 40.0 (29.8–50.0)
Overall (test of stochastic ordering)‡ Z  1.74 Z  7.99 Z  4.60
P  0.0819 P  0.0001 P  0.0001
Data are median (5–95%). *P  0.05 former intensive treatment group (INT) vs. former conventional treatment group (CONV). †P  0.01 INT vs. CONV. ‡The
test of stochastic ordering tests whether the majority of the measures show differences in a single direction, thus favoring one treatment group over the other.
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during the DCCT.
In the current analyses, prior treat-
ment-group differences in the prevalence
of conﬁrmed clinical neuropathy per-
sisted 13–14 years after DCCT closeout,
despite the rapid, post-DCCT disappear-
ance of glycemic separation, reﬂecting
both improvement of glycemic control in
the former conventional treatment group
and worsening of glycemic control in the
former intensive treatment group. All sig-
niﬁcant differences in measures of neu-
ropathy favored the former intensive
treatment group over the former conven-
tional treatment group. The absolute risk
reduction was relatively small at EDIC
years 13–14, but glycemic separation had
not existed for nearly a decade. Despite
this persistent effect of prior treatment,
the current results are disappointing in
that 34% of subjects in the former inten-
sive treatment group and 41% of those in
the former conventional treatment group
developed clinical neuropathy, and 25
and 35% of the former intensive and con-
ventional treatment groups, respectively,
developed conﬁrmed clinical neuropa-
thy. The higher prevalence of most indi-
catorsofneuropathyateachevaluationin
the secondary intervention cohort com-
paredwiththeprimarypreventioncohort
is consistent with those participants hav-
ing a longer duration of diabetes. The
prevalence of neuropathy 13–14 years af-
ter DCCT closeout seems high but may
not be when compared with other stud-
ies. At EDIC years 13–14, the duration of
diabetesaveraged23yearsamongthepri-
mary prevention cohort and 30 years
among the secondary intervention co-
hort. Previous estimates have suggested
that 50% of patients with a 25-year his-
tory of diabetes have neuropathy (17). By
this measure, the prevalence of neuropa-
thy identiﬁed in NeuroEDIC may be
lower than anticipated.
Analyses show that former intensive
therapyhadalong-termeffectonincident
conﬁrmed clinical neuropathy among
subjects free of this outcome at DCCT
closeout (supplemental Table 5a). How-
ever, previous analyses have suggested
that the categorical deﬁnitions of neurop-
athy inadequately adjust for the levels of
subclinical neuropathy at DCCT closeout
(12). When the analysis of each clinical
outcome was adjusted for the mean rank
of the 10 NCS measures at DCCT close-
out, the effect was no longer statistically
signiﬁcant. These ﬁndings indicate that
the long-term beneﬁcial effects of inten-
sive therapy on clinical neuropathy in the
EDIC study could be explained by the re-
sidual difference between groups in the
NCSs among patients at DCCT closeout.
Analyses also show that intensive
treatment had signiﬁcant long-term ben-
eﬁcial effects on NCS measures in the
EDICstudy,bothindividuallyandoverall
(Table3).However,afteradjustingforthe
residual NCS differences at DCCT close-
out, differences persisted for 3 of 10 NCS
measures, all from the lower extremity
and among those most likely to be abnor-
mal in mild diabetic neuropathy. Thus,
metabolic memory may apply to neurop-
athy as well as retinopathy and nephrop-
athy, but part of its long-term effect is
mediated by treatment group differences
in residual subclinical NCS results at
closeout among subjects who remain
asymptomatic. However, the current
analyses cannot exclude the possibility of
apriorandmorerobusteffectattributable
to metabolic memory that diminished or
resolved 13–14 years after DCCT close-
out.Indeed,themagnitudeoftheeffectof
prior intensive treatment on diabetic ret-
inopathy has diminished over time (18).
Our study had some limitations. The
deﬁnition of clinical neuropathy used in
the DCCT and the EDIC study required
appropriate symptoms and signs, based
on the neurologist’s interpretation of the
neurological examination. Absolute val-
ues of normality were then used for
electrodiagnostic measures to identify
conﬁrmed clinical neuropathy. A criti-
cism of our use of the electrodiagnostic
results may be that adjustments were not
made for potential confounders, such as
height, when determining whether NCS
results were normal. Regardless, there
was considerable agreement between the
clinical and electrodiagnostic measures of
neuropathy. The initial analyses also did
not exclude subjects identiﬁed to have
competing cause for neuropathy. In sub-
sequent analyses, history forms were re-
viewed to identify subjects who were
receiving (or who had received) medica-
tions associated with peripheral neuro-
toxicity (n  4) or subjects who had
conditions thought by the examining
neurologisttocontributetoorexplainthe
subject’sneuropathy(n5).Repeatanal-
yses excluding this small number of sub-
jectsshowedresultssimilartotheoriginal
results including all subjects (data not
shown).
In summary, we found that the re-
ducedprevalenceofneuropathyresulting
from former intensive treatment of pa-
tients with type 1 diabetes persisted for at
least 13–14 years. However, the current
ﬁndings are disappointing in terms of the
cumulative frequency of neuropathy and
do not support the initial optimism that
the effects of diabetes on the peripheral
nervous system attributable to hypergly-
cemia could be arrested. Intensive treat-
ment appears important but insufﬁcient
to delay progression or to prevent devel-
opment of diabetic neuropathy in many
subjects. Although models that adjusted
for NCS differences at DCCT closeout
based on a composite NCS score failed to
show signiﬁcant treatment group differ-
ences for incident neuropathy, we found
support for the concept of metabolic
memory on the NCS measures when we
used more powerful analyses that ad-
justed for the actual NCS values at
closeout.
Despite the substantial prevalence of
neuropathy among the NeuroEDIC par-
ticipants, the results of the current study
Table4—Incidenceofclinicalneuropathy,abnormalNCSs,andconﬁrmedclinicalneuropathy
at DCCT closeout and EDIC years 13–14 among subjects who did not fulﬁll the speciﬁc
criterion for neuropathy at the preceding evaluation
Variable DCCT baseline DCCT closeout EDIC years 13–14
Clinical neuropathy
INT 57/600 (10) 57/533 (11)† 145/505 (29)
CONV 48/581 (8) 96/526 (18) 154/448 (34)
Abnormal NCSs
INT 185/601 (31) 73/410 (18)† 195/430 (45)
CONV 196/582 (34) 137/382 (36) 151/290 (52)
Conﬁrmed clinical neuropathy
INT 39/600 (7) 32/551 (6)† 117/541 (22)
CONV 31/581 (5) 75/543 (14) 136/479 (28)‡
Dataaren(%).†P0.001formerintensivetreatmentgroup(INT)vs.formerconventionaltreatmentgroup
(CONV). ‡P  0.125.
Albers and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 1095provide further evidence of the impor-
tance of good glycemic control. Incident
and prevalent neuropathy at EDIC years
13–14 were strongly inﬂuenced by the
mean A1C levels from DCCT baseline
throughtheNeuroEDICassessment,con-
ﬁrming that poor glycemic control is a
signiﬁcant and robust predictor of
neuropathy.
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